Evidence map›Paper›PMID 35776316›Full record

ArticleCell biochemistry and biophysics2022

ZAKβ Alleviates Oxidized Low-density Lipoprotein (ox-LDL)-Induced Apoptosis and B-type Natriuretic Peptide (BNP) Upregulation in Cardiomyoblast.

Yueh-Min Lin, Jiro Hasegawa Situmorang, Jia-Zun Guan, Dennis Jine-Yuan Hsieh, Jaw-Ji Yang, Michael Yu-Chih Chen, Ching-Hui Loh, Chia-Hua Kuo, Shang-Yeh Lu, Ying-Ming Liou and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Yueh-Min LinSchool of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Jiro Hasegawa SitumorangCardiovascular and Mitochondrial Related Disease Research Center, Buddhist Tzu Chi General Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Jia-Zun GuanDepartment of Life Sciences, National Chung-Hsing University, Taichung, Taiwan.
Dennis Jine-Yuan HsiehSchool of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
Jaw-Ji YangSchool of Dentistry, Chung-Shan Medical University, Taichung, Taiwan.
Michael Yu-Chih ChenDepartment of Cardiology, Buddhist Tzu Chi General Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Ching-Hui LohDepartment of Family Medicine and Medical Research, Buddhist Tzu Chi General Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Chia-Hua KuoLaboratory of Exercise Biochemistry, University of Taipei, Taipei, Taiwan.
Shang-Yeh LuDivision of Cardiovascular Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.
Ying-Ming Liou *Department of Life Sciences, National Chung-Hsing University, Taichung, Taiwan.
Chih-Yang Huang *Cardiovascular and Mitochondrial Related Disease Research Center, Buddhist Tzu Chi General Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan. cyhuang.tc@gmail.com.
Buddhist Tzu Chi General Hospital · TWChung Shan Medical University · TWNational Chung Hsing University · TWChina Medical University · TWWilliams (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidized low-density lipoprotein (ox-LDL) is a type of modified cholesterol that promotes apoptosis and inflammation and advances the progression of heart failure. Leucine-zipper and sterile-α motif kinase (ZAK) is a kinase of the MAP3K family which is highly expressed in the heart and encodes two variants, ZAKα and ZAKβ. Our previous study serendipitously found opposite effects of ZAKα and ZAKβ in which ZAKβ antagonizes ZAKα-induced apoptosis and hypertrophy of the heart. This study aims to test the hypothesis of whether ZAKα and ZAKβ are involved in the damaging effects of ox-LDL in the cardiomyoblast. Cardiomyoblast cells H9c2 were treated with different concentrations of ox-LDL. Cell viability and apoptosis were measured by MTT and TUNEL assay, respectively. Western blot was used to detect apoptosis, hypertrophy, and pro-survival signaling proteins. Plasmid transfection, pharmacological inhibition with D2825, and siRNA transfection were utilized to upregulate or downregulate ZAKβ, respectively. Ox-LDL concentration-dependently reduces the viability and expression of several pro-survival proteins, such as phospho-PI3K, phospho-Akt, and Bcl-xL. Furthermore, ox-LDL increases cleaved caspase-3, cleaved caspase-9 as indicators of apoptosis and increases B-type natriuretic peptide (BNP) as an indicator of hypertrophy. Overexpression of ZAKβ by plasmid transfection attenuates apoptosis and prevents upregulation of BNP. Importantly, these effects were abolished by inhibiting ZAKβ either by D2825 or siZAKβ application. Our results suggest that ZAKβ upregulation in response to ox-LDL treatment confers protective effects on cardiomyoblast.

Indexed as

Lipoproteins, LDLNatriuretic Peptide, BrainAnimalsApoptosisHypertrophyMAP Kinase Kinase KinasesProtein KinasesRatsUp-RegulationLipoproteins, LDLMap3k20 protein, ratMAP Kinase Kinase KinasesNatriuretic Peptide, Brainoxidized low density lipoproteinProtein KinasesApoptosisBNPCardiac hypertrophyOxidative stressOxidized low‐density lipoproteinZak

Identifiers

PMID35776316
OpenAlexW4283748827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.